Clinical trial
A Study to Test the Effectiveness and Safety of a New Medication in the…
NCT00088634 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00088634 |
|---|---|
| Title | A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia |
| Official title | A Double-blind Fixed-dose Study of Lurasidone (SM-13496) and Placebo in the Treatment of Schizophrenia |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Lurasidone, Placebo |
| Enrollment | 180 |
| Start date | May 1, 2004 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Aug 2, 2004 |
| Last update posted | Apr 8, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: